Radius Health Inc history

2008 Abaloparatide-SC Phase 2 trial initiated in postmenopausal women with osteoporosis.

2011 Abaloparatide-SC Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial initiated in postmenopausal women with osteoporosis.

2012 Radius and 3M Drug Delivery Systems announced exclusive agreement for development of abaloparatide-TD. Radius initiated Phase 2 Study of abaloparatide-TD for the Treatment of Postmenopausal Osteoporosis.

2013 Abaloparatide-SC Phase 3 extension study (ACTIVExtend) commenced.

2014 Radius commenced elacestrant Phase 1 study in postmenopausal women with ER+ and HER2- advanced breast cancer in the United States.

2015 Radius commenced a Phase 1 FES-PET study in patients with metastatic breast cancer in the European Union, which includes the use of FES-PET imaging to assess estrogen receptor occupancy in tumor lesions following elacestrant treatment.

TYMLOS® (abaloparatide) injection was approved on April 28, 2017 by the United States Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

2018 Radius initiated its Phase 3 EMERALD study, a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in advanced/metastatic ER-positive (ER+)/HER2-negative (HER2-) breast cancer patients.

2019 Radius initiated the Phase 3 wearABLe study to evaluate the efficacy and safety of abaloparatide-TD for the treatment of postmenopausal women with osteoporosis.

2020 Radius successfully sells its second oncology pipeline asset – RAD140 – to Ellipses Pharma Limited, completing Radius’ divestment of its oncology assets.